Brainstorm Cell Therapeutics (BCLI) Competitors $1.14 -0.03 (-2.56%) Closing price 07/3/2025 03:55 PM EasternExtended Trading$1.15 +0.01 (+1.23%) As of 07/3/2025 04:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock BCLI vs. ITRM, KPTI, AKTX, ACRV, CLNN, VOR, EGRX, ELYM, BRNS, and LVTXShould you be buying Brainstorm Cell Therapeutics stock or one of its competitors? The main competitors of Brainstorm Cell Therapeutics include Iterum Therapeutics (ITRM), Karyopharm Therapeutics (KPTI), Akari Therapeutics (AKTX), Acrivon Therapeutics (ACRV), Clene (CLNN), Vor Biopharma (VOR), Eagle Pharmaceuticals (EGRX), Eliem Therapeutics (ELYM), Barinthus Biotherapeutics (BRNS), and LAVA Therapeutics (LVTX). These companies are all part of the "pharmaceutical products" industry. Brainstorm Cell Therapeutics vs. Its Competitors Iterum Therapeutics Karyopharm Therapeutics Akari Therapeutics Acrivon Therapeutics Clene Vor Biopharma Eagle Pharmaceuticals Eliem Therapeutics Barinthus Biotherapeutics LAVA Therapeutics Brainstorm Cell Therapeutics (NASDAQ:BCLI) and Iterum Therapeutics (NASDAQ:ITRM) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their profitability, media sentiment, earnings, dividends, analyst recommendations, risk, valuation and institutional ownership. Do insiders & institutionals hold more shares of BCLI or ITRM? 14.3% of Brainstorm Cell Therapeutics shares are held by institutional investors. Comparatively, 9.2% of Iterum Therapeutics shares are held by institutional investors. 11.2% of Brainstorm Cell Therapeutics shares are held by company insiders. Comparatively, 9.2% of Iterum Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth. Which has higher valuation & earnings, BCLI or ITRM? Iterum Therapeutics is trading at a lower price-to-earnings ratio than Brainstorm Cell Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBrainstorm Cell TherapeuticsN/AN/A-$11.62M-$3.36-0.34Iterum TherapeuticsN/AN/A-$24.77M-$0.99-0.96 Does the media refer more to BCLI or ITRM? In the previous week, Iterum Therapeutics had 3 more articles in the media than Brainstorm Cell Therapeutics. MarketBeat recorded 4 mentions for Iterum Therapeutics and 1 mentions for Brainstorm Cell Therapeutics. Iterum Therapeutics' average media sentiment score of 0.18 beat Brainstorm Cell Therapeutics' score of 0.00 indicating that Iterum Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Brainstorm Cell Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Iterum Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Which has more risk & volatility, BCLI or ITRM? Brainstorm Cell Therapeutics has a beta of 0.22, meaning that its share price is 78% less volatile than the S&P 500. Comparatively, Iterum Therapeutics has a beta of 2.79, meaning that its share price is 179% more volatile than the S&P 500. Do analysts recommend BCLI or ITRM? Brainstorm Cell Therapeutics presently has a consensus price target of $30.00, suggesting a potential upside of 2,531.58%. Iterum Therapeutics has a consensus price target of $9.00, suggesting a potential upside of 846.37%. Given Brainstorm Cell Therapeutics' higher possible upside, equities analysts plainly believe Brainstorm Cell Therapeutics is more favorable than Iterum Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Brainstorm Cell Therapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Iterum Therapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Is BCLI or ITRM more profitable? Company Net Margins Return on Equity Return on Assets Brainstorm Cell TherapeuticsN/A N/A -519.50% Iterum Therapeutics N/A N/A -71.37% SummaryBrainstorm Cell Therapeutics and Iterum Therapeutics tied by winning 5 of the 10 factors compared between the two stocks. Get Brainstorm Cell Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for BCLI and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding BCLI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BCLI vs. The Competition Export to ExcelMetricBrainstorm Cell TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$11.22M$2.88B$5.50B$9.02BDividend YieldN/A2.43%5.38%4.10%P/E Ratio-0.3421.5627.5520.29Price / SalesN/A245.31389.87112.84Price / CashN/A41.9536.6357.47Price / Book-0.847.518.075.68Net Income-$11.62M-$55.05M$3.17B$249.04M7 Day Performance7.55%4.61%2.83%3.30%1 Month Performance1.79%4.89%3.70%5.20%1 Year Performance-77.80%5.84%35.41%21.37% Brainstorm Cell Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BCLIBrainstorm Cell Therapeutics4.1282 of 5 stars$1.14-2.6%$30.00+2,531.6%-77.8%$11.22MN/A-0.3440Gap DownITRMIterum Therapeutics1.4532 of 5 stars$0.94-4.6%$9.00+852.8%-15.1%$37.78MN/A-0.9510KPTIKaryopharm Therapeutics3.8658 of 5 stars$4.33-1.1%$43.20+897.7%-62.8%$37.41M$145.24M-0.33380AKTXAkari Therapeutics1.0046 of 5 stars$1.16+3.6%N/A-62.9%$37.33MN/A0.009ACRVAcrivon Therapeutics2.6712 of 5 stars$1.18flat$17.71+1,401.2%-78.9%$36.99MN/A-0.5358CLNNClene2.3139 of 5 stars$4.10-4.2%$40.00+875.6%-39.9%$36.82M$340K-1.01100News CoverageVORVor Biopharma4.0201 of 5 stars$0.29+20.7%$7.06+2,333.5%+104.9%$36.24MN/A-0.18140Analyst RevisionGap UpHigh Trading VolumeEGRXEagle PharmaceuticalsN/A$2.79-3.0%N/A-45.5%$36.23M$257.55M0.00100Gap DownELYMEliem TherapeuticsN/A$1.21-1.6%N/A-81.6%$36MN/A-2.289BRNSBarinthus Biotherapeutics2.853 of 5 stars$0.89+5.7%$6.25+603.0%-31.8%$35.86M$14.97M-0.54107News CoverageGap UpLVTXLAVA Therapeutics1.8674 of 5 stars$1.33+1.1%$3.17+139.0%-25.8%$34.86M$11.98M-1.2760 Related Companies and Tools Related Companies ITRM Competitors KPTI Competitors AKTX Competitors ACRV Competitors CLNN Competitors VOR Competitors EGRX Competitors ELYM Competitors BRNS Competitors LVTX Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:BCLI) was last updated on 7/4/2025 by MarketBeat.com Staff From Our PartnersPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredSpecial gold investment soars 2,300% ... 5,090% ... 9,850%In my 54 years as an investor, I’ve seen my share of gold bull markets. But nothing comes close to the rall...Weiss Ratings | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | Sponsored379 passengers walked away from thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredPost-Halving = Profit Season (Here’s How to Win It)It happens like clockwork. Every four years, the crypto market enters a new phase — and for those who know how...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Brainstorm Cell Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Brainstorm Cell Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free BCLI Stock Alerts